Precise pathological diagnosis is crucial for proper management of patients suffering from cancer. There are approximately 100 known tumor types of the central nervous system. Due to Large number of tumor type standardization of the diagnostic process is very challenging. Researchers are now working on a completely different approach which is DNA methylation-based classification of CNS tumors across all entities and age groups. They have shown its application in a routine diagnostic setting. Results have shown that the availability of this method may have a significant impact on diagnostic precision compared to currently available methods, resulting in a change of diagnosis in up to 12% of prospective cases. To increase the accessibility, Researchers have designed a free online classifier tool, no additional onsite data processing is required to use the tool. Results have provided a blueprint for the generation of machine learning based tumor classifiers across other cancer types.
DelveInsight Blog
Related Article
![pharma-news-for-alnylam-bms-daichii-sankyo-vertex pharma-news-for-alnylam-bms-daichii-sankyo-vertex](https://assets.delveinsight.com/blog/wp-content/uploads/2024/06/25155241/pharma-news-for-alnylam-bms-daichii-sankyo-vertex.png)
Alnylam’s HELIOS-B Phase III Study of Vutrisiran; Bristol Myers Squibb Secures FDA Nod for KRAZATI and Cetuximab; Daichii Sankyo’s EZHARMIA® Receives Japan Approval; Vertex’s Phase I/II VX-880 Trial; argenx’s VYVGART Hytrulo FDA Approval
Alnylam's HELIOS-B Phase III Study of Vutrisiran Shows Positive Results, Meeting All Primary and Secondary Endpoints Alnylam Pharmaceuticals, Inc. reported encouraging topline outcomes from its HELIOS-B Phase III study of vutrisiran, an experimental RNAi therapy being developed to treat ATTR amyloidosis with car...
Find More![pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms](https://assets.delveinsight.com/blog/wp-content/uploads/2024/06/18150914/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms.png)
Takeda Showcase Phase III Results for Soticlestat; Imfinzi and Chemotherapy Combination Gains US Approval; Nipocalimab Shows Notable Efficacy in Phase II Study; Bristol Myers Squibb’s Augtyro FDA Approval; AstraZeneca’s Farxiga FDA Approval
Takeda Reveals Phase III Results for Soticlestat (TAK-935) in Dravet and Lennox-Gastaut Syndromes Takeda revealed topline results from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase III trial assessing soticlestat (TAK-935) plus standard care against plac...
Find More![pharma-news-for-moderna-almirall-lilly-ipsen pharma-news-for-moderna-almirall-lilly-ipsen](https://assets.delveinsight.com/blog/wp-content/uploads/2024/06/11141344/pharma-news-for-moderna-almirall-lilly-ipsen.png)
Moderna’s Phase III Trials for Dual Influenza and COVID-19 Vaccine; Almirall’s Klisyri FDA Approval; Lilly’s Tirzepatide MASH Trial; Cycle Pharmaceuticals Acquisition of Vanda Pharmaceuticals; Ipsen’s Iqirvo FDA Approval
Moderna Reports Successful Phase III Trials for Dual Influenza and COVID-19 Vaccine Moderna, Inc. has reported that its Phase III trial for mRNA-1083, an experimental combination vaccine targeting both influenza and COVID-19, achieved its main objectives by generating a stronger immune response than the approved...
Find MoreEditor's Pick
Newsletter/Whitepaper
Recent Article
ASCO Conference 2024
![ASCO 2023 ASCO 2023](https://assets.delveinsight.com/img/events/american-society-of-clinical-oncology-conference-2024.png)
Live Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!